Related references
Note: Only part of the references are listed.Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman et al.
CIRCULATION (2022)
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Javed Butler et al.
CIRCULATION (2022)
SGLT2 inhibitors: the statins of the 21st century
Eugene Braunwald
EUROPEAN HEART JOURNAL (2022)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors et al.
NATURE MEDICINE (2022)
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial
Milton Packer et al.
CIRCULATION (2021)
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee
Thomas M. Maddox et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
Dragana Nikolic et al.
DIABETES THERAPY (2021)
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
Vishal N. Rao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Michael E. Nassif et al.
NATURE MEDICINE (2021)
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
David D. Berg et al.
JAMA CARDIOLOGY (2021)
Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
Jordi Real et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
Donna Shu-Han Lin et al.
DIABETOLOGIA (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D. Solomon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017
Jean M. Lawrence et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie et al.
JAMA INTERNAL MEDICINE (2021)
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Ja Young Jeon et al.
DIABETES & METABOLISM JOURNAL (2021)
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Xiaoxuan Ma et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship
Michael A. Nauck
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials
Mirna Abd El Aziz et al.
DIABETES OBESITY & METABOLISM (2020)
European Society of Cardiology: Cardiovascular Disease Statistics 2019
Adam Timmis et al.
EUROPEAN HEART JOURNAL (2020)
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)
Kevin Damman et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
David R. Powell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Donna H. Ryan et al.
AMERICAN HEART JOURNAL (2020)
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
Matthew J. Crowley et al.
DIABETES CARE (2020)
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Enrico Longato et al.
CARDIOVASCULAR DIABETOLOGY (2020)
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
Darren K McGuire et al.
Lancet Diabetes & Endocrinology (2020)
GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials
Chuqing Cao et al.
ENDOCRINE (2020)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri T. Kato et al.
CIRCULATION (2019)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Donna K. Arnett et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
Christian Anholm et al.
ATHEROSCLEROSIS (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
Bjorn Pasternak et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events A Post Hoc Analysis of a Randomized Clinical Trial
Subodh Verma et al.
JAMA CARDIOLOGY (2019)
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
Janet B. McGill et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Henrik Svanstrom et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study
Uchenna Anyanwagu et al.
AMERICAN HEART JOURNAL (2018)
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
N. H. Cho et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg et al.
DIABETOLOGIA (2018)
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
Mikhail Kosiborod et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data
Edward W. Gregg et al.
LANCET (2018)
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Hao Zhou et al.
REDOX BIOLOGY (2018)
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Jonathan D. Newman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
CIRCULATION (2017)
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
DIABETOLOGIA (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
Zeqing Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2017)
6. Obesity Management for the Treatment of Type 2 Diabetes
DIABETES CARE (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Abd A. Tahrani et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association of Fitness in Young Adulthood With Survival and Cardiovascular Risk The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Ravi V. Shah et al.
JAMA INTERNAL MEDICINE (2016)
Dose-Response Relationship Between Physical Activity and Risk of Heart Failure A Meta-Analysis
Ambarish Pandey et al.
CIRCULATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cardiovascular Complications of Diabetic Kidney Disease
Ragnar Palsson et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2014)
Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study)
Jennifer L. Jarvie et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Diabetes: a 21st century challenge
Paul Z. Zimmet et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice
Sanjeewa A. Goonasekera et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Dose Response Between Physical Activity and Risk of Coronary Heart Disease A Meta-Analysis
Jacob Sattelmair et al.
CIRCULATION (2011)
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M. A. Nauck et al.
DIABETOLOGIA (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Exercise-induced reduction in obesity and insulin resistance in women: A randomized controlled trial
R Ross et al.
OBESITY RESEARCH (2004)
Share Paper
